Entellus Medical

Investor Relations

We are a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of patients in the physician office setting or operating room who are suffering from chronic sinusitis. Our XprESS family of products is used by ear, nose and throat, or ENT, physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation to treat patients with symptomatic inflammation of the nasal sinuses.
Stock Information
ENTL (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%)0.00 (0.00%)
Data as of 02/27/18 4:00 p.m. ET
Minimum 15 minute delay
Refresh quote
Stock chart for: ENTL.O.  Currently trading at $24.00 with a 52 week high of $25.58 and a 52 week low of $11.47.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
Financial Reconciliations
Non-GAAP Financial Measure Reconciliations - Click Here
Recent NewsMore >>
12/07/17Entellus Medical Announces Definitive Agreement to be Acquired by Stryker Corporation for a Purchase Price of $24.00 Per Share in Cash
11/14/17Entellus Medical to Participate in Upcoming Investor Conferences
11/13/17Anthem Inc. Issues Positive Coverage Decision for Balloon Sinus Dilation
11/01/17Entellus Medical Announces Third Quarter 2017 Financial Results
Upcoming EventsMore >>
There are currently no events scheduled.